1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Prevalence of Diverse Range Of Diseases
6.1.2 Rise in Technology Advancements and Innovations
6.1.3 Increase in Healthcare Expenditure
6.1.4 Patent Expiration of Blockbuster Drugs
6.2 Market Restraints
6.2.1 Huge Capital Investment with Low Profit Margins
6.2.2 Stringent Government Regulations
6.3 Opportunities
6.4 Challenges
7. Market Segmentation
7.1 By Drug Type
7.1.1 Small Molecule Drug
7.1.2 Biologics Drug
7.2 By Technology
7.2.1 High Throughput Screening
7.2.2 Biochips
7.2.3 Bioinformatics
7.2.4 Pharmacogenomics and Pharmacogenetics
7.2.5 Combinatorial Chemistry
7.2.6 Nanotechnology
7.2.7 Spectroscopy
7.2.8 Metabolomics
7.2.9 Others
7.3 By Service
7.3.1 Drug Metabolism and Pharmacokinetics (DMPK) Services
7.3.2 Pharmaceutical Services
7.3.3 Chemical Services
7.3.4 Biological Services
7.4 By End-User
7.4.1 Research Institutes
7.4.2 Pharmaceutical Companies
7.4.3 Biotechnology Companies
7.4.4 Others
7.5 Segmentation by Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 United Kingdom
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia & New Zealand
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East and Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of Middle East and Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Pfizer Inc
9.2 Glaxosmithkline Llc
9.3 Merck & Co. Inc
9.4 Agilent Technologies Inc
9.5 Eli Lilly and Company
9.6 F. Hoffmann-La Roche Ltd
9.7 Bayer Ag
9.8 Abbott Laboratories Inc
9.9 Astrazeneca Plc
9.10 Shimadzu Corp
9.11 Others
10. Future of The Market

Pfizer inc
Glaxosmithkline llc
Merck & Co inc
Agilent Technologies inc
Eli Lilly and Company
F. Hoffmann-La Roche ltd
Bayer ag
Abbott Laboratories inc
Astrazeneca plc
Shimadzu corp